Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Vaccinex Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VCNX
Nasdaq
8731
https://www.vaccinex.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Vaccinex Inc
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
- Apr 2nd, 2024 12:30 pm
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
- Mar 27th, 2024 12:30 pm
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
- Feb 21st, 2024 1:00 pm
Vaccinex, Inc. Announces Reverse Stock Split
- Feb 15th, 2024 1:00 pm
Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc
- Feb 12th, 2024 4:03 pm
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
- Feb 7th, 2024 1:00 pm
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
- Dec 4th, 2023 1:00 pm
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 1:00 pm
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
- Oct 31st, 2023 1:00 pm
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
- Oct 26th, 2023 1:30 pm
Vaccinex Announces Pricing of $9.6 Million Public Offering
- Sep 29th, 2023 1:00 am
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
- Sep 28th, 2023 12:00 pm
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
- Sep 27th, 2023 12:00 pm
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
- Sep 26th, 2023 12:00 pm
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Aug 14th, 2023 12:10 pm
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
- Jun 1st, 2023 12:00 pm
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
- May 15th, 2023 8:45 pm
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
- Apr 25th, 2023 12:00 pm
Scroll